omalizumab

CHEBI:CHEBI_750461

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

active_ingredient_strength
150 mg/1.2mL
active_ingredient_name
OMALIZUMAB
unii
2P471X1Z11
spl_set_id
7f6a2191-adfb-48b9-9bfa-0d9920479f0d
nui
N0000175792
pharm_class_epc
Anti-IgE [EPC]
pharm_class
IgE-directed Antibody Interactions [MoA]
pharm_class_pe
Decreased IgE Activity [PE]
pharm_class_moa
IgE-directed Antibody Interactions [MoA]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
generic_name
Omalizumab
rxcui
2673763
brand_name
Xolair PFS
brand_name_base
Xolair PFS
product_type
BULK INGREDIENT
listing_expiration_date
20251231
marketing_start_date
20180928
dosage_form
LIQUID
package_marketing_start_date
20180928
route
SUBCUTANEOUS
marketing_category
BULK INGREDIENT
labeler_name
NOVARTIS PHARMA SAS
manufacturer_name
Genentech, Inc.
product_ndc
0078-1336
application_number
BLA103976
spl_id
ddc8a331-35fe-4c1a-bf63-f8a419b2baf3
package_ndc
0078-1336-09
package_description
2 kg in 1 BOTTLE (0078-1336-09)